Atika Capital Management LLC Vertex Pharmaceuticals Inc Transaction History

Atika Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $5.11 Million - $6.31 Million	13,000 New	13,000 $6.09 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $1.8 Million - $2.37 Million	-8,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $1.6 Million - $1.98 Million	8,000 New	8,000 $1.9 Million
Q2 2019 Aug 12, 2019	SELL	$164.61 - $190.37 $4.28 Million - $4.95 Million	-26,000 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $900,515 - $1.07 Million	5,500 Added 26.83%	26,000 $4.78 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $379,775 - $480,525	2,500 Added 13.89%	20,500 $3.4 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $1.01 Million - $1.16 Million	6,000 Added 50.0%	18,000 $3.47 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $437,160 - $509,880	-3,000 Reduced 20.0%	12,000 $2.04 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $454,800 - $531,390	3,000 Added 25.0%	15,000 $2.45 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $1.65 Million - $1.87 Million	12,000	12,000 $1.8 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.